Search
Everyone knows that cigarettes cause cancer. But what do we know about how they do it?
Research fellow Shaniqua Hayes joined the Jason Lewis Lab at the Sloan Kettering Institute (SKI) and Memorial Hospital about a year ago, after attending an online postdoc recruiting event and picking up “good vibes” about SKI.
In a pivotal move to revolutionize the clinical research landscape, the MSK Clinical Research Innovation Consortium (CRIC) held its inaugural kick-off meeting in November 2025. Spearheaded by founding member MSK, the meeting welcomed new CRIC members Moffitt Cancer Center, Huntsman Cancer Institute, and the Tisch Cancer Center of Mount Sinai Health System.
In contrast with the findings of two international trials, Memorial Sloan Kettering Cancer Center data suggest the standard treatment – primary debulking surgery – may provide better outcomes in select patients when compared to neoadjuvant chemotherapy.
Memorial Sloan Kettering Cancer Center (MSK) today announced a $50 million gift from Jane and Daniel Och to advance MSK’s cutting-edge patient-care and research.
Of the estimated 1.5 million people diagnosed with cancer each year in the United States, more than 126,000 are between the ages of 20 and 45. Many young cancer patients want to have children after their treatment is completed, and many will be able to have children naturally at that time. However, some patients will lose their ability to conceive a child without the help of procedures designed to assist with reproduction. Unfortunately, many young patients are not adequately informed of and prepared for the risks to fertility that may accompany cancer and some cancer treatments.
An international collaboration of researchers is advancing precision medicine for men with advanced prostate cancer.
Memorial Sloan Kettering Cancer Center (MSK) experts presented breakthrough findings in several areas of cancer research at the 2022 Annual ASCO meeting, focusing on rectal, breast, leptomeningeal metastasis, pancreatic, and lung cancers.
Memorial Sloan Kettering Cancer Center (MSK) announces its most recent awards and appointments for the institution’s physicians, scientists, nurses, and staff.
A team led by MSK molecular biologist Scott Lowe is making progress against fibrolamellar hepatocellular carcinoma.